Indaptus Therapeutics (INDP) Income towards Parent Company (2020 - 2026)

Indaptus Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 51.77% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$18.3 million (down 11.19% YoY), while the FY2025 annual figure was -$80.6 million, down 11.42% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$2.2 million, up from -$8.2 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$2.2 million in Q1 2026, with the low at -$8.2 million in Q4 2025.
• The 5-year median for Income towards Parent Company is -$4.2 million (2024), against an average of -$4.2 million.
• The sharpest annual moves came in 2025 and 2026: Income towards Parent Company plunged 94.88% in 2025, then surged 51.77% in 2026.
• Indaptus Therapeutics' Income towards Parent Company stood at -$3.9 million in 2022, then decreased by 7.04% to -$4.2 million in 2023, then increased by 0.18% to -$4.2 million in 2024, then slumped by 94.88% to -$8.2 million in 2025, then soared by 72.89% to -$2.2 million in 2026.
• Business Quant data shows INDP's Income towards Parent Company at -$2.2 million in Q1 2026, -$8.2 million in Q4 2025, and -$2.7 million in Q3 2025.